Patent directory · USPTO A61K / A61P
Patents matching “ARCUTIS BIOTHERAPEUTICS, INC.”
24 pharma patents match "ARCUTIS BIOTHERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 24 pharmaceutical patents matching "ARCUTIS BIOTHERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12390453
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12336983
Inhibition of crystal growth of roflumilast
granted -
US 12329751
Topical roflumilast formulation having antifungal properties
granted -
US 12310956
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 12257242
Inhibition of crystal growth of roflumilast
granted -
US 12220409
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12161643
Stable formulations of SHR0302
granted -
US 12144802
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
granted -
US 12083122
Laureth-4 containing topical formulations
granted -
US 12053481
Compositions and methods for deep dermal drug delivery
granted -
US 12042558
Method and formulation for improving roflumilast skin penetration lag time
granted -
US 12042487
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12016848
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12011437
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12005051
Topical roflumilast formulation having improved delivery and plasma half life
granted -
US 12005052
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 11992480
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 11819496
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 11793796
Inhibition of crystal growth of roflumilast
granted -
US 11730740
Laureth-4 containing topical formulations
granted -
US 11707454
Topical roflumilast formulation having antifungal properties
granted -
US 11628177
Compositions and methods for deep dermal drug delivery
granted -
US 11534493
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
granted -
US 11129818
Topical roflumilast formulation having improved delivery and plasma half life
granted